89 results about "ProteinChips" patented technology

The invention discloses a chip for diagnosing the proteins. The antigens corresponding to multiple relevant indexes are printed on the different positions of the membrane of cellulose nitrate. The multi-tape immunoblotting method is utilzied through the coloration of gold mark or the precipitation enzyme without coloration to detect the antibody in the specimen of the sufferer aiming at the antibodies all antigens. The invention raises the detecting sensitivity and the specificity of the immunizing method so as to avoid the false negative or the false positive, providing the results for detecting multiple antigens in one one-stroke detection. Since the chip possesses more information than the information in the testing sheet so as to reduce the collecting quantity and shorten the testing period.

The invention relates to a protein chip, a protein chip diagnostic kit, a preparation method and a using method. The protein chip contains the following protein markers of autologous antigen protein: a P53 antigen fragment, an SOX2 antigen fragment, a COPB1 antigen fragment, an EFHD2 antigen fragment, an EIF4G3 antigen fragment and a PCNA antigen fragment, wherein the characteristic amino acid sequence of the P53 antigen fragment is as shown in ID.1sequence; the characteristic amino acid sequence of the SOX2 antigen fragment is as shown in ID.2sequence; the characteristic amino acid sequence of the COPB1 antigen fragment is as shown in ID.3sequence; the characteristic amino acid sequence of the EFHD2 fragment is as shown in picture 4seeqeunce; the characteristic amino acid sequence of the EIF4G3 antigen fragment is as shown in ID.5seqeunce; the characteristic amino acid sequence of the PCNA antigen fragment is as shown in ID.6sequence. Early diagnosis or general investigation screening for suspected patients of lung cancer or high-risk population of lung cancer can be carried out extremely conveniently, quickly, noninvasively and efficiently.

The invention discloses application of a serum molecular marker combination as a lung cancer diagnosis and curative effect monitoring marker, belonging to the field of immunodetection. The content of protein (OPN, SAA, CRP, CEA, CYFRA21.1, MIF, AGP, HGF, E-selectin, GRO and NSE) in 11 serums is measured through a Luminex protein chip diagnosis technology. The eight serum protein molecular markers are OPN, SAA, CRP, CYFRA21.1, CEA, NSE, AGP and HGF. The eight serum protein molecular markers have significant promotion effect on a non-small cell lung cancer (NSCLC) and a small cell lung cancer (SCLC). A three-protein detection combination formed by OPN, CEA and another protein (CRP, SAA, CYFRA21.1 or NSE) has excellent diagnosis potential on NSCLC. Compared with the prior art, the serum molecular marker combination has the beneficial effects that the content of multiple protein molecular markers of serum of a patient with lung cancer is detected, and the serum molecular marker combination can be used for lung cancer diagnosis and curative effect monitoring through coordinated comparative analysis of the multiple protein molecular markers.

The invention discloses a visual protein chip for detecting serum antibody of new-castle disease virus of chickens, infectious bronchitis virus of chickens, avian influenza virus and infectious bursal disease virus of chickens , which is prepared by the following steps: purifying and diluting whole proteins of the four virus respectively; pointing samples of the positive control serum, the negative control serum and the four virus proteins onto a chip carrier respectively; drying, fixing, sealing and washing the samples to obtain the visual protein chip. The visual protein chip uses the purified whole proteins as capturing antigens to detect the virus-specific antibodies in chicken serum so as to simplify the preparation technology and reduce the production cost, and the visual protein chip has better specificity but no cross, has high reliability of results and has the advantages of quickness, simplicity and convenience, high sensitivity, good specificity and the like. When the serum is diluted by 6,400 times, the visual protein chip still can detect the antibodies, the sensitivity is 400 times of that of the prior AGP detection method. According to the detection to serum samples in-place, the detection rate of the visual protein chip is higher than the proir AGP method remarkably.

The invention discloses a kit for identifying a new coronavirus by applying a mass spectrum system and a use method of the kit. The kit comprises the following components: a U9 buffer solution, a U1 buffer solution and a sodium acetate buffer solution. The using method of the kit comprises the following steps: S1, activating a metalloprotein chip target plate; S2, pretreating a serum sample; S3, extracting protein in the serum sample by using the metalloprotein chip target plate; and S4, acquiring and processing a spectrogram by using an MALDI-TOF mass spectrum system, and analyzing the read spectrogram by using software. Therefore, the kit is high in sensitivity, good in accuracy, simple and convenient to operate, short in consumed time and very suitable for clinical diagnosis.

The invention belongs to the technical field of biology, and particularly discloses a method for quantitatively detecting a protein acetylation level. The method particularly comprises the steps of preparing protein chips, drawing standard curves and detecting actual samples. The method overcomes the defects that antibodies have weak affinities and acetylated protein is difficult to enrich efficiently when acetylation antibodies are subjected to immune precipitation enriching directly; the protein acetylation level can be quantitatively detected quickly and simply; the used sample amount is less; the difference comparison among the different samples is facilitated; the study of an acetylation difference spectrogram provides a technology platform for establishing high-flux protein acetylation difference spectral analysis; and a predictive value of an acetylation state for liver cancer metastasis can be investigated.

The invention relates to a recombinant rubella virus E1 protein and an application thereof. The adopted technical proposal is as follows: the amino acid sequence of the recombinant rubella virus E1 is shown in SEQ ID NO: 2, a reagent kit which is prepared by the recombinant rubella virus E1 protein and used for detecting the rubella virus IgM antibody infection is adopted, compared with the similar reagent kits on the market, the reagent kit has the advantages of strong specificity, high sensitivity, and the like, thereby well meeting the needs of clinical diagnosis of rubella virus infection. The invention further provides the application of the recombinant rubella virus E1 protein in the preparation of monoclonal antibodies, polyclonal antibodies and protein chips.

This invention relates to one functional central neutral damage dialogue test protein chip and its process method, which comprises the following steps: using protein chip to fix multiple central neutral system damage generation development key function abnormal protein factor antigen and its array; the said protein antigen and its array abnormal protein factors act as key property protein factors in the neutral system for inflammation and activation reaction and cell ion balance adjust and signal transmission.

The present invention discloses one kind of gene recombinant human cytomegalovirus fusion protein pp150/MDBP and its preparation process and application, and relates to gene engineering technology, preventing vaccine, diagnosis reagent and other technology. The recombinant fusion protein pp150/MDBP is fusion protein formed through connecting serially the 197th amino acid in the 495-691 amino acid segment of human cytomegalovirus pp150 and the 64th amino acid in the 538-601 amino acid segment of MDBP protein. The 197th amino acid pp150 in the N-terminal of the fusion protein and the 64th amino acid of MDBP protein in the C-terminal of the fusion protein are connected through two amino acids including one Leu and one Glu, and the fusion protein has one increased Met and has whole length of 264 amino acids. The fusion protein is used in detecting human cytomegalovirus antibody and antigen, preparing antibody and protein chip, vaccine, ELISA detecting kit and other products.

The invention provides a protein chip for typing detection on helicobacter pylori infection. The protein chip comprises a basement membrane and antigens which are respectively dotted on the basement membrane in the form of dot matrix, wherein the antigens include three types, i.e. CagA (cytotoxin-associated gene) antigens, VacA (Vacuolating cytotoxin A) antigens and Ure (ureaplasma urealyticum) antigens. Due to the fact that the detection antigens used by the protein chip are three single proteins, i.e. Ure, CagA and VacA, specific IgG antibodies for the three antigens in the blood serum of a patient can be detected at the same time, I-type infection or II-type infection can be judged, and clinic treatment is better facilitated; furthermore, the protein chip has the advantages of high detection sensitivity, quick, simple and convenient detection, instant readability, small using amount of antigen and the like.

The invention discloses a method for seeking micromolecule chemical drug target spots by combining a quantum dot nanometer fluorescent probe and a protein chip, comprising the steps of: connecting a quantum dot with a micromolecule chemical drug to form a quantum dot-micromolecule chemical drug fluorescent probe; then directly incubating the fluorescent probe and the protein chip together; after washing, determining the binding sites (target spots) of specificities between the drug and known proteins fixed on the chip according to fluorescence given out by the optical excitation of the quantum dot on the protein chip; and analyzing the proteins at the binding sites through computer software. According to the method for seeking micromolecule chemical drug target spots by combining the quantum dot nanometer fluorescent probe and the protein chip, the micromolecule chemical drug and the target proteins having efficacy on cells can be simply, conveniently and rapidly sought, and an efficient technical means for screening novel micromolecule chemical drugs in a high-throughput manner can be provided.

The invention belongs to the field of biomedicine, providing a method for detecting animal pathogenic microorganisms and a special protein chip thereof. The detecting method essentially comprises the following steps of: a. preparing the protein chip, selecting a plurality of different groups of specific antigen of many kinds of pathogenic microorganisms by means of an experiment to be fixed on a properly modified carrier; and b. detecting: reacting blood serum of a animal to be detected with the protein chip, hybridizing with a marked secondary antibody, detecting a hybrid positive signal in a proper detection way, and obtaining a hybrid result of the blood serum and the chip by means of scanning and analyzing, wherein the blood serum infected with the different pathogenic microorganisms can show different positive signal combination modes after the reaction, so as to ensure whether the animal to be detected is infecting or is infected with the pathogenic microorganisms marked on the protein chip. The invention can simultaneously detect many kinds of the pathogenic microorganisms, improves detecting efficiency, selects many groups of different antigen with a certain specificity aiming at each pathogenic microorganism, leads the detection to have good specificity, and has good application prospect in detecting the animal pathogenic microorganisms.

The invention discloses a combined general check protein chip for early-stage cancers mainly comprising lung cancer and belongs to the technical field of a protein chip. The combined general check protein chip for the early-stage cancers mainly comprising the lung cancer, provided by the invention, comprises a chip substrate and marker antibodies distributed on the chip substrate, wherein the chip substrate is an FAST protein chip substrate having a three-dimensional nitrocellulose basic material; one or more sample application module is arranged on the FAST protein chip substrate; the following marker antibodies are fixed on the sample application module: 14-3-3 theta, LAMR-1, TSGF (Tumor Specific Growth Factor), CEA (Cancer Embryo Antigen), SCC (Squamous Cell Carcinoma), CYFRA21-1 and positive control; the following marker antibodies are also fixed: AFP (Alpha Fetal Protein), CA242, MG-Ag, CA199, TPA (Tissue Polypeptide Antigen) and EA-IgA; and the following marker antibodies are further fixed: CA125, CA153, SF (Serum Ferritin) and PSA (Prostate Specific Antigen). According to the combined general check protein chip provided by the invention, the related indexes are highly integrated; the combined general check protein chip has the advantages of excellent stability, strong specificity, long retention period, high sensitivity, excellent repeatability, convenience in operation and low cost; the labor efficiency is increased; and a cancer patient is diagnosed and treated from the general check before clinical symptoms occur.

The invention belongs to the field of molecular biology and oncology, and particularly relates to a group of esophageal cancer detection markers and application thereof in preparation of an esophagealcancer screening kit. The esophageal cancer detection markers serve a reagent capable of specifically detecting CA19-9, CYFRA21-1, CA125, FBXW7 and FAT1 or a group of gene expression products; the esophageal cancer early diagnosis kit is a liquid-phase protein chip kit. According to the esophageal cancer marker, a combination of the CA19-9 monoclonal antibody, the CYFRA21-1 monoclonal antibody, the CA125 monoclonal antibody, the FBXW7 monoclonal antibody and the FAT1 monoclonal antibody is used as the esophageal cancer marker for the first time, and is applied to preparation of a liquid-phaseprotein chip with high detection sensitivity and specificity for early esophageal cancer, the detection sensitivity of the liquid-phase protein chip to esophageal cancer is 93.5%, and the specificityof the liquid-phase protein chip to esophageal cancer is 73.9%.

The invention discloses an up-conversion luminescent marker based on an up-conversion luminescent marker, a protein chip and a detection method. The array of biologically active molecules on a glass slide or other carrier medium has a detection antibody fixed at the detection site, which can detect It specifically binds to the target antigen of the immune complex, and the quality inspection antibody is immobilized on the quality inspection site, which will specifically bind to the antigen of the quality inspection substance in the pretreatment solution; the excitation device of the line scan is a near-infrared light source. The dichroic mirror is irradiated on the protein chip, and the detection device of the line scanning technology is a line array camera, which simultaneously collects the visible light intensity signals emitted by each point on the line. The UCNP of the present invention cross-links bioactive molecules in a covalent manner, which improves the reliability and stability of the system on the premise of ensuring the detection sensitivity.

The invention discloses a protein chip for combined detection of multiple thrombus markers. A preparation method of the protein chip comprises the following steps: (1) black slide pretreatment; (2) antibody solution sample application; (3) a sealing process; and preparation of the protein chip. The protein chip is used for detecting concentrations of various thrombus markers, preventing and reducing thrombus risks and guiding thrombus treatment. The product disclosed by the invention is a protein chip diagnostic kit comprising six indexes of TAT (thrombin-antithrombin complex), PIC (plasmin-alpha2 anti-plasminogen complex), tPAIC (tissue-type plasminogen activator-plasminogen activation inhibition complex), TM (thrombomodulin), FDP (fibrinogen degradation product) and DD (D-dimer). The indexes are detected by using a protein chip technology for the first time, and the method has the advantages of quickness, high efficiency, simplicity, convenience, low cost and the like.

The invention relates to the technical field of biology, in particular to a preparation method an application of a protein chip for detecting pet infection markers. The preparation method of the protein chip comprises the following steps: (1) carrying out pretreatment on a glass slide; (2) performing sample application on an antibody solution; (3) preparing the protein chip by using a sealing process. The protein chip provided by the invention is used for the dog and cat infection markers; after the protein chip technology originated by the company is applied to realization of joint detection,the detection efficiency is effectively improved, and the detection cost is lowered; the inventor develops a protein chip diagnostic kit capable of realizing canine C-reactive protein (CRP)/serum amyloid A (SAA) double-test, canine CRP/SAA/CPL triple-test, feline CRP/SAA double-test and feline CRP/SAA/FPL triple-test; the preparation method has the advantages of being fast, high in efficiency, low in cost, and the like.

The invention belongs to the technical field of biological medicines and particularly relates to a biological marker group for optic neuromyelitis spectrum diseases, application of the biological marker group, a protein chip and a kit. The invention provides an optic neuromyelitis spectrum disease biomarker group which is characterized by comprising monocyte chemotactic protein-3, LIGHT, macrophage inflammatory protein-1 delta, insulin-like growth factor-2, a glucocorticoid induced tumor necrosis factor receptor, thrombopoietin and a herpes virus entry medium, wherein the LIGHT is a lymphotoxin analogue which can be induced and expressed on a T cell and competes with glycoprotein D of HSV to be combined with HVEM. The application fills the blank that no reliable and accurate product and method for diagnosing and identifying optic neuromyelitis lineage diseases exist clinically at present.

The invention discloses a protein combination for diagnosing a Q fever. The protein combination consists of the following proteins from (1) to (7): (1) a protein of which the amino acid sequence is represented by SEQ ID NO: 1, (2) a protein of which the amino acid sequence is represented by SEQ ID NO: 2, (3) a protein of which the amino acid sequence is represented by SEQ ID NO: 3, (4) a protein of which the amino acid sequence is represented by SEQ ID NO: 4, (5) a protein of which the amino acid sequence is represented by SEQ ID NO: 5, (6) a protein of which the amino acid sequence is represented by SEQ ID NO: 6, and (7) a protein of which the amino acid sequence is represented by SEQ ID NO: 7. The protein combination and a protein chip can perform quick and accurate serology analysis and diagnosis on blood serum of a human or an animal having the Q fever; the result is accurate and reliable; moreover, the operation is simple, the number of used samples is low, the time and the labor are saved, and the protein combination is desired to be substituted for the conventional complicated, tiring and time-consumed serology diagnosis method for Q fever serology diagnosis.

The invention discloses a Hepatitis C virus variation detection protein chip as well as a preparation method and application thereof. The invention mainly adopts colloid gold-silver dye detection system to replace original fluorescent marker of the chip, with the application of the detection system of the invention, a chip fluorescent scanner is unnecessary, only by visual detection and simple image scanning can the reaction result of the chip be judged, thus realizing the aim of HCV variation detection. Compared with the fluorescent detection system, the invention is more suitable for fundamental medical treatment organs, can be applied to prognosis of HCV diseases, prediction of curing effect of interferon and the like, and has certain clinical application prospect.

The invention provides a construction method of a novel coronavirus N-His recombinant protein chip platform. The construction method comprises the following steps: firstly, preparing N recombinant protein with good antigenicity through pET28a N plasmids; and then determining the optimal dilution of the first antibody and the second antibody by using the N recombinant protein, and finally determining the detection limit and the linear range of the chip by using the constructed chip to detect the serum subjected to gradient dilution, thereby completing the construction of the N gene recombinantprotein chip platform. Compared with an RT-PCR detection method, the chip has more stable detection performance, also has the characteristics of high throughput, microminiaturization and the like, isnot easily influenced by virus variation, and can more accurately and quickly realize large-batch screening of 2019-nCoV.

The utility model discloses a plastic test tube protein chip, and the preparation method and application. The utility model also discloses a detection kit with the main component of the plastic tube protein chip and the application of the detection kit in the disease diagnosis or detection. The plastic tube protein chip introduces various indicators of disease detection, greatly improving the accuracy of disease detection. In addition, the plastic tube protein chip also has the advantages of high sensitivity, high repeatability, high stability, high signal, applicability to large numbers of samples, convenience, safety and low price.